Overview

Mirdametinib is a selective inhibitor of MEK1 and MEK2, two kinases that sit in the RAS-MAPK signalling cascade controlling cell growth. It received FDA approval in February 2025 for neurofibromatosis type 1 (NF1)-associated symptomatic plexiform neurofibromas in patients aged two years and older. Understanding its mechanism clarifies why blocking MEK, rather than the upstream RAS protein, is a rational therapeutic strategy in this disease. The approval expanded the limited pharmacologic options for a tumor type long managed mainly through surgery.

NF1, RAS and the Case for MEK Blockade

NF1 encodes neurofibromin, a protein that normally dampens RAS activity. When NF1 is lost or dysfunctional, RAS becomes overactive and continuously drives the MAPK pathway, promoting the proliferation of the Schwann-cell-rich tumors seen in plexiform neurofibromas. Because directly inhibiting mutant RAS has proven difficult, the field moved downstream to MEK1/2. Mirdametinib binds these kinases and interrupts signal transmission, blunting the growth stimulus at a controllable node. This downstream blockade also spares the broader toxicity that untargeted RAS suppression might otherwise provoke.

Dosing and the Plexiform Neurofibroma Setting

The approved regimen is weight-based at 2 mg per square metre, taken twice daily for the first 21 days of each 28-day cycle, a schedule designed to balance activity with tolerability. In the ReNeu trial (NCT03962543), objective responses were reported in 41 percent of adults and 52 percent of pediatric patients with these tumors. Such figures reflect a defined study population and should be interpreted alongside the full label and individual clinical assessment. Families should receive counseling on the intermittent schedule so doses are not mistakenly taken every day.

Place in Therapy and Monitoring

Mirdametinib offers a systemic option for symptomatic plexiform neurofibromas that may not be amenable to surgery. As with MEK inhibitors generally, clinicians monitor for class-effect toxicities such as rash, cardiac effects, and ocular changes, and counsel families on the intermittent dosing structure. Its mechanism, targeted interruption of a single kinase pair, contrasts with cytotoxic approaches and illustrates the shift toward pathway-directed oncology. Ongoing imaging tracks tumor volume, since symptomatic relief and measurable shrinkage do not always move together.

FAQ

Q: Why target MEK instead of RAS in NF1? A: Directly inhibiting RAS has been hard; MEK1/2 sit just downstream and are pharmacologically tractable, making them a practical control point.

Q: Who is the approved patient population? A: Patients aged two years and older with NF1-associated symptomatic plexiform neurofibromas, per the February 2025 FDA approval.

Q: How is the dose determined? A: It is weight-based at 2 mg per square metre, given twice daily for 21 days of a 28-day cycle.

Q: What do the ReNeu trial response figures mean? A: They describe objective responses in a specific study cohort, 41 percent of adults and 52 percent of children, and are not a guarantee for individual outcomes.